Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Qilian International Holding Group Limited (BGM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: BGM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -76.62% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 46.83M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) 20471 | Beta 1.42 | 52 Weeks Range 2.70 - 14.78 | Updated Date 02/26/2025 |
52 Weeks Range 2.70 - 14.78 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -26.32% | Operating Margin (TTM) -5.41% |
Management Effectiveness
Return on Assets (TTM) -3.84% | Return on Equity (TTM) -16.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21573068 | Price to Sales(TTM) 1.57 |
Enterprise Value 21573068 | Price to Sales(TTM) 1.57 | ||
Enterprise Value to Revenue 0.72 | Enterprise Value to EBITDA -2.48 | Shares Outstanding 4826480 | Shares Floating 1612611 |
Shares Outstanding 4826480 | Shares Floating 1612611 | ||
Percent Insiders - | Percent Institutions 0.12 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Qilian International Holding Group Limited
Company Overview
History and Background
Qilian International Holding Group Limited was founded to focus on the manufacturing and distribution of traditional Chinese medicine (TCM) products. Details regarding specific founding years and milestones are currently unavailable and not well documented in readily accessible public sources.
Core Business Areas
- Pharmaceutical Products: Manufactures and distributes pharmaceutical products, including Traditional Chinese Medicine (TCM) based medicines and other related products.
- Nutritional Products: Manufactures and distributes nutritional products and supplements. Details of specific market presence is lacking.
Leadership and Structure
Information on the current leadership team and organizational structure is not readily available in public domain sources. Lack of transparency could impact data sourcing and assessment.
Top Products and Market Share
Key Offerings
- Traditional Chinese Medicine (TCM) Products: Qilian produces TCM based medicines. Precise market share data and revenue contributions are unavailable. Competitors in the broader TCM market include large pharmaceutical companies with TCM divisions and smaller, specialized TCM manufacturers.
- Nutritional Supplements: Qilian produces nutritional supplements. Market share and revenue contributions are unavailable due to limited data. Competitors include major nutritional supplement brands and other local Chinese manufacturers.
Market Dynamics
Industry Overview
The TCM industry in China is a large and growing market, driven by increasing demand for natural and holistic healthcare solutions. The market for nutritional supplements is also expanding due to rising health awareness among consumers.
Positioning
Qilian's positioning within the TCM and nutritional supplement markets is challenging to ascertain due to limited market share data. Their competitive advantage, if any, is difficult to define based on publicly available information.
Total Addressable Market (TAM)
The TAM for TCM and nutritional supplements in China is estimated to be in the billions of USD. However, Qilian International Holding Group Limited's market share and positioning relative to the TAM is unknown due to the lack of publicly verifiable data.
Upturn SWOT Analysis
Strengths
- Potential for growth in the expanding Chinese TCM market
- Established manufacturing capabilities
Weaknesses
- Lack of financial transparency
- Limited publicly available information
- Small market capitalization
- Potentially delisted from NASDAQ
Opportunities
- Expanding into new TCM product lines
- Capitalizing on growing demand for nutritional supplements
- Strategic partnerships and collaborations
Threats
- Intense competition in the TCM and supplement markets
- Regulatory changes impacting the pharmaceutical industry
- Economic downturns in China
- Potential delisting from NASDAQ
Competitors and Market Share
Key Competitors
Competitive Landscape
Due to the lack of publicly verifiable data, providing an accurate comparative analysis to competitors is not possible.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Analysis of historical growth is difficult due to limited data availability.
Future Projections: Reliable future growth projections cannot be made due to data scarcity and high uncertainty.
Recent Initiatives: Information on recent strategic initiatives is limited.
Summary
Qilian International Holding Group Limited's financial position and market standing are difficult to assess due to a lack of readily available and reliable data. The company operates in a growing industry, but faces considerable competitive pressure. The opacity of its financial disclosures and the potential for delisting from NASDAQ raise significant concerns. Therefore, investing in this stock is risky.
Similar Companies
Sources and Disclaimers
Data Sources:
- Public company filings (where available)
- Limited news sources
- Market research reports (general industry data)
Disclaimers:
The data and analysis provided are based on limited publicly available information and should not be considered financial advice. Investing in Qilian International Holding Group Limited carries significant risks, including potential delisting and financial opacity. Conduct thorough due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qilian International Holding Group Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-12 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 298 | Website https://www.bgm.ltd |
Full time employees 298 | Website https://www.bgm.ltd | ||
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.